Recently, Yichang Renfu Pharmaceutical Co., Ltd. received a marketing authorization approval letter issued by the French National Agency for the Safety of Medicines and Health Products (ANSM) for its midazolam injection. The approved indications are: 1. Conscious sedation before, during, and after diagnostic or therapeutic procedures (whether or not combined with local anesthesia). 2. Preoperative medication before anesthesia induction in adults, anesthesia induction, and use with other anesthetics as a sedative; preoperative medication before anesthesia induction in children. 3. Sedation in the intensive care unit (ICU).

The approval of Yichang Renfu's midazolam injection in the EU marks another successful registration of an injection in the EU, following the successful registrations of hydromorphone hydrochloride injection and remifentanil hydrochloride for injection. This provides more product support for further opening up the EU market and signifies a new level of competitiveness for the company's anesthetic and analgesic products in the high-end international market.

In the future, Yichang Renfu will continue to cultivate the field of anesthesia and analgesia, accelerate the pace of overseas market development, and continuously help the company achieve its ambitious goal of "becoming a leader in the field of anesthesia and analgesia and creating a world-class pharmaceutical enterprise".